2ND CONFERENCE VALIDATION OF BIOMARKERS

Date & Time March 28, 2019
Address Hotel Bildungszentrum 21
Missionsstrasse 21, 4055
Basel, Switzerland

Translating biomarker candidates from discovery to the clinic remains a challenge. This second symposium organised by the Clinimark project will examine how integrated technologies can bridge the innovation gap with an initial focus on lung diseases. EATRIS provides support to the organisation of the event with speakers from EATRIS institutions in the programme. Clinicians, clinical chemists or scientists active in the biomarkers’ field are invited to join this symposium. Peter Groenen, Head of Translational Sciences of Idorsia Pharmaceuticals will open the event together with Theo Luider from Erasmus MC and coordinator of the Clinimark project.

Deadline for registrations:  March 20, 2019.

Keynote speaker:

Joseph Menetski, PhD. Associate Vice President of Research Partnerships – Director of the Biomarkers Consortium, the Foundation for the National Institutes of Health, USA

Scientific topics that will be discussed:

  • Biomarker research and development
  • Biomarker validation process and techniques
  • Biomarker FDA regulation
  • Pulmonary Diseases including COPD, oncology, cystic fibrosis
  • Biobanking and data stewardship
  • Technologies (mass spectrometry, multiplex immunoassays, new approaches to quantify proteins in body fluids and breath condensate)

The topics covered are designated for:

  • Clinicians
  • Clinical chemists
  • Biologists (molecular biology, biochemistry, epidemiology)
  • Scientists with an interest in biomarker technology
  • Industrial scientists (start-up, diagnostic, pharmaceutical, biotechnological

You can follow this link to register or find more information.

Agenda:

09.15 – 09.30: Opening of the symposium: Peter Groenen, PhD. Head of Translational Sciences, Idorsia Pharmaceuticals Ltd, Switzerland; Theo Luider, PhD. Erasmus MC, The Netherlands
09.30 – 10.15: Joseph Menetski, PhD. Associate Vice President of Research Partnerships – Director of the Biomarkers Consortium, the Foundation for the National Institutes of Health, USA
10.15 – 10.40: Claudia Steurer-Stey, Prof. Dr. med, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland – TBC

10.40 – 11.10: Coffee break

11.10 – 11.35: Andrea Motta, PhD. Istituto di Chimica Biomolecolare del CNR, Italy
11.35 – 12.00: Maria Jose Cruz, PhD. Pneumology Research Group, Vall d’Hebron Research Institute (VHIR), Spain
12.00 – 12.25: Marian Hajduch, Prof. Dr. med, Director, Institute of Molecular and Translational Medicine (IMTM), Czech Republic
12.25 – 12.50: Vincent Mooser, Prof. Laboratory Medicine, Head Clinical Chemistry, Lausanne university hospital (CHUV), Switzerland

12.50 – 14.15: Lunch

14.15 – 14.40: Rainer Bischoff, Prof. Head Department of Analytical Biochemistry. University of Groningen, the Netherlands
14.40 – 15.10: Monica Marchese, PhD. Biomarker Validation Scientist, Integrated Biobank of Luxembourg (IBBL), Luxembourg
15.10 – 15.35: Daniel Strasser PhD. Associate Director, Idorsia Pharmaceuticals Ltd., Switzerland

16.00 – 16.30: Break

16.30 – 16.55: Peter Blattman, PhD. Postdoctoral Scientist, Institute of Molecular Systems Biology (ETH), Switzerland
16.55 – 17.20: Alain van Gool, Prof. Head Translational Metabolic Laboratory, Radboudumc, The Netherlands
17.20 – 17.45: Laurenz Baltzer, Strategy Competence Lead, Karger AG, Switzerland

Website by Lewis+Humphreys